Skip to Main Content

Advertisement

Skip Nav Destination

Issues

IN THIS ISSUE

J Immunol (2019) 202 (10): 2821.

IMMUNOLOGY NOTES AND RESOURCES

J Immunol (2019) 202 (10): 2823–2828.

BRIEF REVIEWS

J Immunol (2019) 202 (10): 2829–2835.

CUTTING EDGE

J Immunol (2019) 202 (10): 2837–2842.

  • Tal1 limits the number of ST-HSC priming lymphoid genes.

  • Tal1 limits the number of Rag2-GFP+ LMPPs.

  • Tal1 restrains the frequency of T lymphocyte–biased LMPPs.

J Immunol (2019) 202 (10): 2843–2848.

  • CLP-induced polymicrobial sepsis has the capacity to attenuate tumor growth.

  • Sepsis reinvigorates tumor-infiltrating CD8 T cells.

  • Checkpoint blockade after sepsis further improves survival of tumor-bearing hosts.

ANTIGEN RECOGNITION AND RESPONSES

J Immunol (2019) 202 (10): 2849–2855.

  • Proteomics analysis shows the upstream proline signature of HLA class I ligands.

  • Proline at upstream positions 1–3 attenuates CTL responses to a downstream epitope.

  • The finding contributes to prediction of naturally presented CTL epitopes.

J Immunol (2019) 202 (10): 2856–2872.
J Immunol (2019) 202 (10): 2873–2887.

  • Trogocytosis-mediated signaling promotes IL-4 expression and TH2 differentiation.

  • TH2 cells perform trogocytosis more efficiently than TH1 or nonpolarized cells.

  • In vivo–generated, trogocytosis-positive cells are predominantly TH2.

AUTOIMMUNITY

J Immunol (2019) 202 (10): 2888–2906.

  • The covalent BTK inhibitor evobrutinib blocks B cell and myeloid cell activation.

  • Evobrutinib is efficacious in mouse models for RA, SLE, and cutaneous anaphylaxis.

  • Covalent binding allows modeling the relationship between BTK occupancy and efficacy.

J Immunol (2019) 202 (10): 2907–2923.

  • Nur77 expression correlates with the degree of autoreactivity of individual B cells.

  • Nur77 is dispensable for receptor editing, central deletion, and anergy.

  • Nur77 restrains the survival of mature self-reactive B cells.

CLINICAL AND HUMAN IMMUNOLOGY

J Immunol (2019) 202 (10): 2924–2944.

  • TLR9-primed human B-CLL clones respond to IL-15 with AKT and STAT5 activation.

  • PI3K/AKT and STAT5 pathways elevate cyclin D2 and repress ATM, TP53BP1, and MDC1.

  • Inhibitors of PI3K or STAT5 block in vitro B-CLL cycling induced by CpG DNA and IL-15.

J Immunol (2019) 202 (10): 2945–2956.

  • The pharmacological activity of Imprime is dependent on naturally occurring serum ABA.

  • A threshold of IgG ABA is necessary for Imprime-mediated innate immune responses.

  • It is likely that high-ABA subjects will be more prone to infusion-related reactions.

IMMUNE REGULATION

J Immunol (2019) 202 (10): 2957–2970.

  • The otubain YOD1 fine-tunes MAVS-RLR pathway–mediated antiviral immunity.

  • YOD1 interacts with MAVS on mitochondria.

  • YOD1 deubiquitinates MAVS and abrogates aggregation of MAVS.

J Immunol (2019) 202 (10): 2971–2981.

  • Arf6 partially colocalized with PLD1 on vesicles and with PLD2 at the plasma membrane.

  • Active Arf6 is recruited to nascent phagosomes.

  • Arf6 regulates PLD activity and PA synthesis during phagocytosis.

J Immunol (2019) 202 (10): 2982–2990.

  • Myeloid-specific conditional deletion of BVR-A results in increased response to LPS.

  • Macrophages isolated from LysM-Cre:BVRfl/fl showed elevated levels of C5aR1.

  • Deletion of BVR-A resulted in enhanced macrophage chemotaxis toward C5a.

  • BVR-A–modulated chemotaxis and RANTES levels are dependent in part on C5aR1.

J Immunol (2019) 202 (10): 2991–2998.

  • Bach2 deletion in CD4+ T cells results in preferential Tfh cell differentiation.

  • The CXCR5 induction in the absence of Bach2 occurs before the upregulation of Ascl2.

  • Bach2 is critical for CD4+ T cell memory, including Tfh cell memory.

J Immunol (2019) 202 (10): 2999–3007.

  • LCs express LIGHT, and chimeras lacking LIGHT in LCs have reduced skin DC migration.

  • Lymphatic endothelial cell–specific LTβR is required for skin DC migration.

  • LIGHT-LTβR signaling axis activates lymphatic endothelial CCL21/CCL19 expression.

IMMUNE SYSTEM DEVELOPMENT

J Immunol (2019) 202 (10): 3008–3019.

  • Malt1 is required for the development and function of Treg cells.

  • Malt1 protease activity in Treg cells could be a target for tumor therapy.

INNATE IMMUNITY AND INFLAMMATION

J Immunol (2019) 202 (10): 3020–3032.

  • Traumatic injury alone without infection can induce emergency hematopoiesis.

  • Trauma induces emergency hematopoiesis through IL-1 -dependent production of G-CSF.

J Immunol (2019) 202 (10): 3033–3040.

  • ZIP requires GM-CSF and IRF4 signaling.

  • The ZIP macrophage phenotype is altered by a lack of GM-CSF or IRF4.

  • GM-CSF–IRF4 signaling upregulated MHCII expression in ZIP macrophages.

  • ZIP is independent of CCL17.

MUCOSAL IMMUNOLOGY

J Immunol (2019) 202 (10): 3041–3052.

  • TLR2 plays a key role in gut serotonin production by both resident microbiota and a parasite.

  • TLR2 in nonhematopoietic cells is largely responsible for serotonin production in the gut.

  • We show TLR2 signaling–based novel mechanism of serotonin production in the gut.

TRANSPLANTATION

J Immunol (2019) 202 (10): 3053–3064.

  • MyD88 deficiency in donor Tcons with Tregs protected against alloreactivity and aGVHD.

  • This protective effect uses ST2 but not the IL-1R or TLR4 pathways.

TUMOR IMMUNOLOGY

J Immunol (2019) 202 (10): 3065–3075.
J Immunol (2019) 202 (10): 3076–3086.

  • PR interacts with STAT1 in breast cancer cells.

  • PR attenuates IFN-induced STAT1 phosphorylation in breast cancer.

  • IFN signaling via STAT1 is more robust in breast cancer cells lacking PR.

J Immunol (2019) 202 (10): 3087–3102.

  • Losartan blocks CCL2–CCR2 monocyte recruitment to suppress lung metastasis growth.

  • Losartan functionally antagonizes CCL2–CCR2 ERK activation, independent of its AT1R target.

NOVEL IMMUNOLOGICAL METHODS

J Immunol (2019) 202 (10): 3103–3112.
Close Modal

or Create an Account

Close Modal
Close Modal